Natco Pharma Limited — PPTs, 12-02-2025: Investor Presentation

NATCO Pharma Limited reported total revenue of INR 6,511 Mn for Q3 FY25, with pharma export formulations contributing INR 2,858 Mn and domestic formulations at INR 961 Mn. The EBITDA of INR 2,151 Mn reflects a margin of 33%, while profit after tax was INR 1,324 Mn, yielding a 20.3% profit margin.

Key developments include a settlement reached by NATCO's partner, Mylan Pharmaceuticals, in the U.S. patent litigation regarding generic Ozempic (Semaglutide), and the declaration of a third interim dividend of INR 1.50 per share. Additionally, NATCO submitted an Abbreviated New Drug Application for the generic version of EVRYSDI (Risdiplam) with a shared First to File status, positioning itself for potential competitive advantage upon launch.

Investors should note these positive dynamics as they reflect on potential growth opportunities and strategic alignments in the competitive pharmaceutical landscape.